Global Filgrastim Biosimilars Market Research Report 2023: Focus on Zarxio, Nivestym, and Releuko
Global Filgrastim Biosimilars Market
Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Filgrastim Biosimilars Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The global filgrastim biosimilars market is expected to grow from $0.75 billion in 2021 to $0.88 billion in 2022 at a compound annual growth rate (CAGR) of 17.2%. The filgrastim biosimilars market is expected to reach $1.19 billion in 2026 at a CAGR of 8.0%.
The filgrastim biosimilars consists of sales of zarxio, nivestym, and releuko. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how it helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections.
North America was the largest region in the filgrastim biosimilars market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main types of manufacturing in filgrastim biosimilar are in-house manufacturing and contract manufacturing organization. A contract manufacturing organization, also known as a contract development and manufacturing organization, is a corporation that provides entire services to other pharma firms on a contractual basis, from drug discovery to drug production.
The different applications include oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.
Government initiatives for the development of biosimilars are expected to drive the filgrastim biosimilars market over the coming years. Governments worldwide are focusing on the development of biosimilars attributing to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options.
The Australian government is committed to the Biosimilar Awareness Initiative and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aid in the increased production and awareness which in turn supported the growth of the filgrastim biosimilars market.
Stringent regulations imposed on approvals of biosimilars are anticipated to hinder the growth of the filgrastim biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars.
Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drugs for biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics.
For instance, Sandoz got USFDA approval for its 1st biosimilar ZarxioTM (filgrastim-and) of original biologic Neupogen. The consent depended on a comprehensive package of analytical, nonclinical, and clinical information, which verified that Zarxio is highly similar to the US-licensed reference product. To get this approval Sandoz even had to fight a legal battle with Amgen which claims that Sandoz has infringed its manufacturing process. These kinds of hurdles can restrict the growth of the filgrastim biosimilar market.
Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies.
While companies have long collaborated as well as academic and research institutions in this market by way of partnerships or out-licensing deals, this trend has been increasing over recent years. For instance, in April 2020, Biocon, an India-based biopharmaceutical company partnered with Mylan, a US-based generic and specialty pharmaceuticals company to introduce Fulphila, biosimilar pegfilgrastim in Australia. Fulphila has been licensed by the Therapeutic Goods Administration for the therapy of oncology patients who have had chemotherapy to shorten the length of acute neutropenia and hence the risk of infection, as evidenced by febrile neutropenia.
In March 2022, Biocon Biologics, an India-based fully integrated biopharmaceutical company, acquired Viatris Inc for $3.3 billion. This acquisition would build a distinctive, fully integrated, global biosimilars enterprise. This strategic alliance combines the strengths and complementary skills of both parties, positioning Biocon Biologics for the next ten years of value generation for all of our stakeholders. Viatris Inc is a US-based pharmaceutical company and developed a biosimilar of pegfilgrastim.
No. of Pages
2022 - 2026
Estimated Market Value (USD) in 2022
Forecasted Market Value (USD) by 2026
Compound Annual Growth Rate
A selection of companies mentioned in this report includes
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Ltd.
Emcure Pharmaceuticals Ltd.
Claris Life Sciences
Teva Pharmaceuticals Industries
F. Hoffmann-La Roche Ltd.
Abbott Laboratories Inc.
Reliance Life Sciences Pvt. Ltd.
Key Topics Covered:
1. Executive Summary
2. Filgrastim Biosimilars Market Characteristics
3. Filgrastim Biosimilars Market Trends And Strategies
4. Filgrastim Biosimilars Market - Macro Economic Scenario
4.1 COVID-19 Impact On Filgrastim Biosimilars Market
4.2 Ukraine-Russia War Impact On Filgrastim Biosimilars Market
4.3 Impact Of High Inflation On Filgrastim Biosimilars Market
5. Filgrastim Biosimilars Market Size And Growth
5.1. Global Filgrastim Biosimilars Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Filgrastim Biosimilars Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Filgrastim Biosimilars Market Segmentation
6.1. Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Chronic and Autoimmune Diseases
Growth Hormone Deficiency
6.2. Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
6.3. Global Filgrastim Biosimilars Market, Segmentation By Type of Manufacturing, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Contract Manufacturing Oraganization
7. Filgrastim Biosimilars Market Regional And Country Analysis
7.1. Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/gjvy9s
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900